PMID-22151630 – Ziconotide Chronic Nonmalignant Pain RCT
Rauck RL, Wallace MS, Leong MS, et al. "A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain," J Pain Symptom Manage, 2006;31(5):393-406.
Quick Reference
| Property | Value |
|---|---|
| PMID | 22151630 |
| DOI | 10.1016/j.jpain.2011.10.003 |
| Year | 2012 |
| Journal | J Pain |
| Study Type | Randomized Controlled Trial |
| Evidence Level | II |
| Sample | n=169 patients with chronic nonmalignant pain |
| Peptide(s) Studied | Ziconotide |
Key Findings
- Intrathecal ziconotide significantly reduced pain intensity in patients with severe chronic nonmalignant pain unresponsive to conventional therapy
- Mean percent reduction in VASPI score was 31.2% for ziconotide vs 6.0% for placebo (P<0.001)
- Efficacy was observed across multiple pain etiologies (neuropathic, nociceptive, and mixed)
- CNS adverse events were common: dizziness, nausea, confusion, abnormal gait, nystagmus
- Slow titration protocol improved tolerability compared to earlier rapid-titration trials
- Demonstrated that ziconotide is effective beyond cancer/AIDS pain populations
Study Design
Multicenter, randomized, double-blind, placebo-controlled trial. Patients with severe chronic nonmalignant pain inadequately controlled by conventional therapy received intrathecal ziconotide or placebo via external microinfusion pump. Slow titration over 3 weeks to maximum tolerated dose, followed by stable-dose maintenance. Primary endpoint: percent change in VASPI score from baseline to end of titration.
Limitations
- Short titration/maintenance period limits long-term conclusions
- High discontinuation rate due to adverse events (~10%)
- External pump system used; may differ from implanted pump experience
- Narrow therapeutic window requiring careful dose titration
- Selected population: only patients who failed multiple prior therapies
Clinical Relevance
This trial extended ziconotide's proven efficacy from cancer/AIDS pain to the broader chronic nonmalignant pain population. The slow titration approach established a practical dosing strategy that improved tolerability while maintaining efficacy. This is significant because chronic nonmalignant pain represents a much larger patient population. The 31.2% vs 6.0% pain reduction demonstrates clinically meaningful benefit in a refractory population. Combined with the JAMA cancer pain trial (PMID-14709577), this RCT solidifies ziconotide's role as a non-opioid option for intractable pain.
Related
#research #RCT #evidence-level-II #ziconotide #pain